Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis.
Ariadni SpyroglouGeorgios KostopoulosSofia TseleniKonstantinos ToulisKonstantinos BramisMastorakos GeorgeManousos KonstadoulakisKyriakos VamvakidisKrystallenia I AlexandrakiPublished in: Cancers (2022)
Although papillary thyroid carcinoma (PTC) is considered to have an excellent prognosis, some recently identified more aggressive variants show reduced overall survival rates. Hobnail PTC (HPTC) was newly recognized as one of these aggressive forms, affecting recurrence, metastasis, and overall survival rates. Herein, we performed a systematic review and meta-analysis of studies including cases or case series with patients with HPTC. Furthermore, we included our individual case series consisting of six patients. The pooled mortality rate in the cohort, consisting of 290 patients, was 3.57 (95% CI 1.67-7.65) per 100 person/years. No sex differences could be observed concerning mortality ( p = 0.62), but older age and tumor size significantly affected mortality ( p = 0.004 and p = 0.02, respectively). The percentage of hobnail cells did not affect mortality ( p = 0.97), neither did the presence of BRAF mutations. Classical characteristics such as the presence of extrathyroidal extension ( p = 0.001), distant metastases ( p < 0.001), and lymph node metastases ( p < 0.001) all had a significant impact on mortality. Thus, HPTC appears to correlate with worse overall survival, and all PTC cases should be carefully assessed for this variant.
Keyphrases
- lymph node
- cardiovascular events
- end stage renal disease
- ejection fraction
- newly diagnosed
- risk factors
- chronic kidney disease
- free survival
- randomized controlled trial
- early stage
- squamous cell carcinoma
- cardiovascular disease
- gene expression
- lymph node metastasis
- clinical trial
- neoadjuvant chemotherapy
- cell proliferation
- middle aged
- endoplasmic reticulum stress
- double blind